scholarly journals Comparative Analysis of the Therapeutic Effects of Amniotic Membrane and Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Type 2 Diabetes

2022 ◽  
Author(s):  
Zhifeng Wang ◽  
Haisen Li ◽  
Jingmeng Fang ◽  
Xiaoyu Wang ◽  
Shuhang Dai ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Comparative Analysis ◽  
Umbilical Cord ◽  
Amniotic Membrane ◽  
Therapeutic Effects

scholarly journals Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells

2019 ◽  
Vol 47 (5) ◽  
pp. 2135-2144
Author(s):  
Xiaoyang Yang ◽  
Shufang Zhang ◽  
Denggao Huang ◽  
Zhiming Wang ◽  
Xiaoxia Chen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Third Party ◽  
Inflammatory Factors ◽  
Cell Bank ◽  
First Case

Hemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation. Mesenchymal stem cells (MSCs) generate an immunosuppressive microenvironment by secreting cytokines and have been used to treat autoimmune diseases. We report the first case of refractory secondary HLH treated with umbilical cord MSCs. A 52-year-old Chinese female patient with a history of type 2 diabetes was diagnosed with refractory secondary HLH based upon the HLH-2004 protocol and was treated by infusion of third-party umbilical cord MSCs (1.4 × 106 cells/kg of body weight, 70 × 106 cells in total) from the stem cell bank of Hainan Province. Body temperature recovered to normal on the sixth day after infusion with umbilical cord MSCs, and the levels of inflammatory factors macrophage inflammatory protein (MIP)-1α, interleukin (IL)-12p70, stromal cell-derived factor (SDF)-1α, and IL-7 decreased significantly. Blood glucose levels were significantly lower than before treatment, and the amount of insulin needed was significantly reduced. Umbilical cord MSCs can relieve the symptoms of refractory secondary HLH and have a therapeutic effect on insulin resistance in type 2 diabetes mellitus.

scholarly journals Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes

2015 ◽  
Vol 9 (5) ◽  
pp. 1623-1630 ◽  
Author(s):  
LI-XUE GUAN ◽  
HUI GUAN ◽  
HAI-BO LI ◽  
CUI-AI REN ◽  
LIN LIU ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Therapeutic Efficacy

scholarly journals Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice

2020 ◽  
Author(s):  
Binghua Xue ◽  
Xiuxiao Xiao ◽  
Tingting Yu ◽  
Xinhua Xiao ◽  
Jie Xie ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Blood Glucose ◽  
Mouse Model ◽  
Therapeutic Effects

Abstract Objective: The purpose of this study was to investigate the therapeutic effects of genetically modified mesenchymal stem cells (MSCs) in the treatment of type 2 diabetes mellitus (T2DM) in order to identify a new method for treating diabetes that differs from traditional medicine and to provide a new means by which to fundamentally improve or treat diabetes. Methods: MSCs derived from adipose tissue were modified to overexpress FGF21 and GLP1, which was achieved through lentiviral particle transduction. The cells were transplanted into BKS.Cg-Dock7m+/+Leprdb/Nju mice (T2DM mouse model). Injections of physiological saline (0.1 mL) and liraglutide (0.5 mg/kg) were used as negative and positive controls, respectively. ELISA or Western blotting were used for protein analysis, and quantitative real-time PCR was used for gene expression analysis. Results: Genetic modification had no effects on the morphology, differentiation ability, or immunophenotype of MSCs. Moreover, MSC-FGF21+GLP1 cells exhibited significantly increased secretion of FGF21 and GLP1. In the T2DM mouse model, the transplantation of MSC-FGF21+GLP1 cells ameliorated the changes in blood glucose and weight, promoted the secretion of insulin, enhanced the recovery of liver structures, and improved the profiles of lipids. Moreover, FGF21 and GLP1 exerted synergistic effects in the regulation of glucolipid metabolism by controlling the expression of insulin, srebp1 and srebp2. Conclusion: Stem cell treatment based on MSCs modified to overexpress the FGF21 and GLP1 genes is an effective approach for the treatment of T2DM. Key words: Type 2 diabetes mellitus; Mesenchymal stem cell; FGF21; GLP1

scholarly journals Glycemic Control by Umbilical Cord-Derived Mesenchymal Stem Cells Promotes Effects of Fasting-Mimicking Diet on Type 2 Diabetes

2021 ◽  
Author(s):  
Na Zhao ◽  
Ying-Feng Gao ◽  
Lei Bao ◽  
Jing Lei ◽  
Huan-Xiao An ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Lipid Metabolism ◽  
Glycemic Control ◽  
Umbilical Cord ◽  
Leptin Receptor ◽  
Human Umbilical Cord ◽  
The Impact

Abstract Background Hepatic steatosis is a big hurdle to treat type 2 diabetes (T2D). Fasting-mimicking diet (FMD) has been shown to be an effective intervention in dyslipidemia of T2D. However, fasting might impair the normal glucose metabolism. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) transplantation has been discovered to regulate immune reactions and reduce hyperglycemia in diabetes. However, the effects of UC-MSCs on improving the lipid metabolism disorder are not quite satisfactory. We have investigated the efficacy comparison and interaction between two typical therapies of FMD and UC-MSC infusion, aiming to pave an avenue for their synergistic use, establish effective T2D therapies and explore its mechanism.Methods C57/BL6 mice were fed with high-fat diet (HFD) for 16 weeks to induce a diet-induced obese (DIO) mouse model. Six-week-old leptin-receptor-deficient (db/db) mice were used for follow-up experiments. DIO or db/db mice were divided into 4 groups: PBS, UC-MSCs (1*106), FMD (entails 4-day FMD and 7-day of refeeding (RF)) and UC-MSCs + FMD. At the end of the study period, mice were fasted for 6 h with the measurement of blood glucose and body weight, and then sacrificed. Blood was collected to determine levels of HbA1c, serum insulin, and cytokines. In addition, the fresh liver, skin and white adipose tissue were analyzed by histology.Results FMD restored the lipid metabolism in DIO mice, whereas its capacity to rescue hyperglycemia was uncertain. Infusion of UC-MSCs was effective in T2D glycemic control but the impact on dyslipidemia was insufficient. Furthermore, both the glucose and the lipid alterations of DIO and db/db mice recovered after UC-MSCs combined with FMD. It was proved that UC-MSCs promoted FMD effects on ameliorating hyperglycemia and restoring the lipid metabolism in T2D mice, while FMD had little promotion effect on UC-MSCs. Mechanistically, we discovered that UC-MSC infusion significantly modulated systematic inflammatory microenvironment, which contributed to concerted actions with FMD.Conclusions We established a strategy that combined UC-MSC infusion and FMD were effective in treating T2D, which synergistically attenuated hyperglycemia and improved the lipid metabolism through immunoregulation. The significance of the work is to provide potential approaches for developing novel clinical T2D therapies.

Sign in / Sign up

Export Citation Format

Share Document